A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE)

Welch, 2015, Trends in metastatic breast and prostate cancer—lessons in cancer dynamics, N Engl J Med, 373, 1685, 10.1056/NEJMp1510443 Mottet, 2017, EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent, Eur Urol, 71, 618, 10.1016/j.eururo.2016.08.003 Hövels, 2008, The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis, Clin Radiol, 63, 387, 10.1016/j.crad.2007.05.022 Suh, 2018, Yield of BS for the detection of metastatic disease in treatment-naive prostate cancer: a systematic review and meta-analysis, Clin Radiol, 73, 158, 10.1016/j.crad.2017.08.004 Jambor, 2016, Prospective evaluation of planar BS, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5 T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial, Acta Oncol, 55, 59, 10.3109/0284186X.2015.1027411 Perera, 2020, Eur Urol, 77, 403, 10.1016/j.eururo.2019.01.049 Hofman, 2020, Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multi-centre study, Lancet, 395, 1208, 10.1016/S0140-6736(20)30314-7 Thoeny, 2014, Metastases in normal-sized pelvic lymph nodes: detection with diffusion-weighted MR imaging, Radiology, 273, 125, 10.1148/radiol.14132921 Komori, 2007, 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: Initial experience, Ann Nucl Med, 21, 209, 10.1007/s12149-007-0010-6 Giesel, 2018, Intraindividual comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study, J Nucl Med, 59, 1076, 10.2967/jnumed.117.204669 Cardinale, 2017, Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen ligand for prostate cancer imaging, J Nucl Med, 58, 425, 10.2967/jnumed.116.181768 Kesch, 2017, 68Ga or 18F for prostate cancer imaging?, J Nucl Med, 58, 687, 10.2967/jnumed.117.190157 Sheikhbahaei, 2019, Prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer: an update on important pitfalls, Semin Nucl Med, 49, 255, 10.1053/j.semnuclmed.2019.02.006 Fendler, 2017, 68 Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0, Eur J Nucl Med Mol Imaging, 44, 1014, 10.1007/s00259-017-3670-z Harris, 2019, The REDCap consortium: building an international community of software platform partners, J Biomed Inform, 95, 10.1016/j.jbi.2019.103208 Lecouvet, 2007, Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies, J Clin Oncol, 25, 3281, 10.1200/JCO.2006.09.2940 Lecouvet, 2012, Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?, Eur Urol, 62, 68, 10.1016/j.eururo.2012.02.020 Calais, 2019, 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial, Lancet Oncol, 20, 1286, 10.1016/S1470-2045(19)30415-2 Brierley, 2017 Hanley, 1983, A method of comparing the areas under receiver operating characteristic curves derived from the same cases, Radiology, 148, 839, 10.1148/radiology.148.3.6878708 Burdett, 2019, Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis, Eur Urol, 76, 115, 10.1016/j.eururo.2019.02.003 Lecouvet, 2018, Use of modern Imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group, Lancet Oncol, 19, e534, 10.1016/S1470-2045(18)30571-0 Fanti, 2018, Consensus on molecular imaging and theranostics in prostate cancer, Lancet Oncol, 19, e696, 10.1016/S1470-2045(18)30604-1 Phillips, 2020, Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial, JAMA Oncol, 6, 650, 10.1001/jamaoncol.2020.0147 Roach, 2018, The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study, J Nucl Med, 59, 82, 10.2967/jnumed.117.197160 Fanti, 2016, Of standard of reference and accuracy: the problem of truth in imaging, Eur J Nucl Med Mol Imaging, 43, 52, 10.1007/s00259-015-3207-2 Ettala, 2020, Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68 ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer, Eur J Nucl Med Mol Imaging, 47, 665, 10.1007/s00259-019-04635-7 Zacho, 2020, Added value of 68Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous 99mTc bone scintigraphy, EJNMMI Res, 10, 31, 10.1186/s13550-020-00618-0 Janssen, 2017, [68 Ga] PSMA-HBED-CC uptake in osteolytic, osteoblastic, and bone marrow metastases of prostate cancer patients, Mol Imaging Biol, 19, 933, 10.1007/s11307-017-1101-y Lantos, 2018, Standard OSEM vs. regularized PET image reconstruction: qualitative and quantitative comparison using phantom data and various clinical radiopharmaceuticals, Am J Nucl Med Mol Imaging, 8, 110